DOCSLIB.ORG

Signalling Pathways Regulating Organ-Specific Endothelial

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Signalling Pathways Regulating Organ-Specific Endothelial REVIEWS The quiescent endothelium: signalling pathways regulating organ- specific endothelial normalcy Nicolas Ricard 1, Sabine Bailly2, Christophe Guignabert 3,4 and Michael Simons 1,5 ✉ Abstract | Endothelial cells are at the interface between circulating blood and tissues. This position confers on them a crucial role in controlling oxygen and nutrient exchange and cellular trafficking between blood and the perfused organs. The endothelium adopts a structure that is specific to the needs and function of each tissue and organ and is subject to tissue-specific signalling input. In adults, endothelial cells are quiescent, meaning that they are not proliferating. Quiescence was considered to be a state in which endothelial cells are not stimulated but are instead slumbering and awaiting activating signals. However, new evidence shows that quiescent endothelium is fully awake, that it constantly receives and initiates functionally important signalling inputs and that this state is actively regulated. Signalling pathways involved in the maintenance of functionally quiescent endothelia are starting to be identified and are a combination of endocrine, autocrine, paracrine and mechanical inputs. The paracrine pathways confer a microenvironment on the endothelial cells that is specific to the perfused organs and tissues. In this Review, we present the current knowledge of organ-specific signalling pathways involved in the maintenance of endothelial quiescence and the pathologies associated with their disruption. Linking organ- specific pathways and human vascular pathologies will pave the way towards the development of innovative preventive strategies and the identification of new therapeutic targets. 1Yale Cardiovascular The endothelium forms the innermost layer of blood ves­ of endothelial­ specific genes in different organs are Research Center, Department sels and lymphatic vessels and is best viewed as a multi­ specified during embryonic development and con­ of Internal Medicine, Yale 12 University School of Medicine, functional organ with both systemic and tissue­specific served during mitotic cycles . Transcriptome analysis of New Haven, CT, USA. roles. At the whole­organism level, the endothelium reg­ endothelial cells from different tissues revealed hetero­ 2Université Grenoble Alpes, ulates oxygen and nutrient supply, immune cell traffick­ geneous gene expression signatures even after several 1 2 INSERM, CEA, BIG- Biologie ing and inflammation , haemostasis and coagulation , passages in cell culture, indicating that tissue­ specific du Cancer et de l’Infection, vasomotor tone3, blood vessel permeability4 and epigenetic modifications participate in the regulation of Grenoble, France. angiogenesis5. In addition, the endothelium has a num­ organotypic transcriptomic profiles13,14. However, after 3INSERM UMR_S 999, ber of organ­ specific functions including regulation long­ term cell culture, which removes endothelial cells Pulmonary Hypertension: of organ size and function (myocardial hypertrophy6, from their in vivo microenvironment, approximately Pathophysiology and 7 8 15 Novel Therapies, Hôpital liver size and function , pulmonary alveolar repair and 50% of gene expression patterns are lost , and major Marie Lannelongue, Le kidney function9,10). architectural characteristics, such as fenestrae, also Plessis- Robinson, France. Given this heterogeneity of endothelial cell function, disappear16. 4Université Paris- Saclay, it is not surprising that studies show a remarkable het­ To characterize organotypic endothelial specificity Faculté de Médecine, erogeneity of gene expression profiles in endothelial cells as close to in vivo conditions as possible, many groups Le Kremlin- Bicêtre, France. from different organs11. Interestingly, these expression have utilized microarray or RNA sequencing (RNA­seq) 5 Department of Cell Biology, profiles are functionally matched to local tissue needs. of endothelial cells isolated by flow cytometry without Yale University School of 11,17 Medicine, New Haven, CT, USA. Microenvironment stimuli (shear stress, hypoxia and the cell culture step . Single­cell RNA­seq of endothe­ ✉e- mail: michael.simons@ the presence of specific growth factors, cytokines lial cells isolated from adult male mice identified tran­ yale.edu and hormones) and epigenetics define and continu­ scriptomic signatures of quiescent arterial, venous, https://doi.org/10.1038/ ously optimize local characteristics of endothelial cells. capillary and lymphatic endothelial cells in 11 differ­ s41569-021-00517-4 Epigenetic signatures that regulate the basal expression ent tissues11. Interestingly, lymphatic endothelial cells NATURE REVIEWS | CARDIOLOGY VOLUME 18 | AUGUST 2021 | 565 0123456789();: REVIEWS Key points has been given to the signalling events that main­ tain endothelial normalcy and quiescence. The latest • Quiescent endothelial cells require active maintenance to preserve normalcy in advances in this area are the subject of this Review. a tissue- specific manner. • Dysregulation of signalling pathways involved in endothelial normalcy maintenance FGF signalling leads to endothelial dysfunction and vascular pathologies. The fibroblast growth factor (FGF) signalling cascade • Endothelial quiescence and normalcy are important for disease resilience. includes a family of 18 ligands, four receptor tyrosine • Identification of organ- specific signalling pathways that maintain endothelial kinases (RTK) (FGFR1–FGFR4) and several accessory normalcy and quiescence will lead to new therapeutic targets supporting disease molecules such as Klotho proteins and syndecans22. resilience and treatment of associated vascular pathologies. After FGFs bind to their high­ affinity RTKs, several intracellular pathways are activated, including the from all the tissues cluster together, suggesting that the phosphoinositide 3­ kinase (PI3K)–AKT pathway and molecular signature of lymphatic endothelial cells is not mitogen­ activated protein kinase (MAPK) pathways tissue­specific. By contrast, arterial and venous endothe­ mediated by extracellular signal­ regulated kinase 1 lial cells from a specific tissue clustered together, show­ (ERK1) and ERK2 (REF.22). ing that vascular endothelial cell heterogeneity comes The extensive structural overlap and cross­ reactivity mainly from tissue specificity rather than arterial, capil­ among FGF ligands and receptors represent a real chal­ lary or venous identity. Moreover, capillary endothelial lenge to identifying the function of FGF signalling in the cells that are involved in gas, ion, metabolite and hor­ endothelium. Results from studies in mice with knock­ mone exchange between the blood and tissues have the out of individual Fgf genes or individual Fgfr genes are highest heterogeneity among tissues11. hard to interpret because of functional redundancy, Structural differences in the capillary endothelium whereas attempts to use FGFR chemical inhibitors are were first described in the 1960s with the use of elec­ hampered by the low specificity and cross­ reactivity tron microscopy18. Three major types of capillaries of these compounds. Successful strategies to circum­ exist (continuous, fenestrated and discontinuous). The vent the redundancy in the FGF family and investigate capillary type of an organ is related to its functions19. FGF signalling include mice with knockout of multiple Most organs have barrier­ forming, continuous capillar­ Fgfr genes (Fgfr1−/−Fgfr2−/− (REF.22) and Fgfr1−/−Fgfr3−/− ies (lungs, brain, skin and heart) with tightly connected (REF.23)), the use of soluble FGFR traps that target vari­ endothelial cells surrounded by a continuous basement ous FGF family members24, and endothelial cell­ specific membrane. This architecture permits diffusion of water, expression of a dominant­negative FGFR1 construct that small solutes and lipid­ soluble materials, while preclud­ can inactivate all four FGF receptors25. Mice with con­ ing the passage of cells or pathogens. By contrast, fenes­ ditional endothelial cell­ specific deletion of Fgfr1 and trated capillaries have intracellular pores (windows) with Fgfr2 are viable, with no vascular developmental defects a diaphragm and are found in renal glomeruli, exocrine and no alterations in vascular homeostasis26. However, glands, endocrine glands and intestinal mucosa. These postnatal endothelial cell­ specific knockout of Fgfr1 in fenestrae increase permeability to fluids and solutes, but mice with global knockout of Fgfr3 results in impaired not macromolecules20. Sinusoids are fenestrated capillar­ development of blood and lymphatic vessels23. A soluble ies with gaps instead of pores between endothelial cells receptor trap strategy was tested with the use of a solu­ and a thinner basement membrane than in continuous ble FGFR1 trap (sFGFR1) that binds to a large number or fenestrated endothelia and are present in the liver, of FGFs24. In this study, transient FGF inhibition was spleen and bone marrow. The gaps found in sinusoids achieved in vivo in mice via adenovirus­ mediated sys­ facilitate selective exchange of materials. temic expression of sFGFR1. This FGF inhibition led to Structural differences notwithstanding, normal an increase in vascular permeability and, eventually, pul­ endothelial cells everywhere are quiescent. This quies­ monary and myocardial haemorrhages, demonstrating cent state is defined by minimal or absent endothelial the necessity for FGF signalling in the maintenance of proliferation and migration, minimal or no vascular
Load more

Recommended publications
  • Clinical Protocol
    OncoMed Pharmaceuticals, Inc. Demcizumab CLINICAL PROTOCOL Protocol No. M18-006 Title: YOSEMITE: A 3-Arm Phase 2 Double-Blind Randomized StudY of Gemcitabine, Abraxane® Plus PlacebO versuS GEMcitabIne, Abraxane® plus 1 or 2 TruncatEd Courses of Demcizumab in Subjects with 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma Version: 23 October 2014 Amendment 1: 24 November 2014 Amendment 2: 10 February 2015 Amendment 3: 28 May 2015 Amendment 4: 31 March 2016 Amendment 5: 19 December 2016 EudraCT Number: 2014‐003355‐56 Sponsor: OncoMed Pharmaceuticals, Inc. 800 Chesapeake Drive Redwood City, CA 94063 Phone: 650-995-8200 CONFIDENTIAL This document contains proprietary and confidential information of OncoMed Pharmaceuticals, Inc. Acceptance of this document constitutes agreement by the recipient that no previously unpublished information contained herein will be published or disclosed without the prior written approval of OncoMed Pharmaceuticals, Inc. with the exception that this document may be disclosed to study personnel under your supervision who need to know the contents for conducting the study and appropriate Institutional Review Boards/Ethics Committees under the condition that the personnel have agreed to keep this information confidential. The foregoing shall not apply to disclosure required by governmental regulations or laws; however, OncoMed Pharmaceuticals, Inc. shall be promptly notified of any such disclosure. Protocol M18-006, Amendment 5 Page 1 of 130 CONFIDENTIAL 19 December 2016 OncoMed Pharmaceuticals, Inc. Demcizumab SPONSOR CONTACTS Medical Monitor: ___________________ (Primary) ___________________________ Email: ___________________ Phone: ____________________ Medical Monitor: ___________________ (Secondary) ___________________ Email: ___________________ Phone: ___________________ Safety Reporting: Europe, Australia Phone: ___________________ Fax: ___________________ United States Phone: ___________________ Fax: ___________________ Protocol M18-006, Amendment 5 Page 2 of 130 CONFIDENTIAL 19 December 2016 OncoMed Pharmaceuticals, Inc.
    [Show full text]
  • Precision Medicine for Human Cancers with Notch Signaling Dysregulation (Review)
    INTERNATIONAL JOURNAL OF MOleCular meDICine 45: 279-297, 2020 Precision medicine for human cancers with Notch signaling dysregulation (Review) MASUKO KATOH1 and MASARU KATOH2 1M & M PrecMed, Tokyo 113-0033; 2Department of Omics Network, National Cancer Center, Tokyo 104-0045, Japan Received September 16, 2019; Accepted November 20, 2019 DOI: 10.3892/ijmm.2019.4418 Abstract. NOTCH1, NOTCH2, NOTCH3 and NOTCH4 are conjugate (ADC) Rova-T, and DLL3-targeting chimeric antigen transmembrane receptors that transduce juxtacrine signals of receptor‑modified T cells (CAR‑Ts), AMG 119, are promising the delta-like canonical Notch ligand (DLL)1, DLL3, DLL4, anti-cancer therapeutics, as are other ADCs or CAR-Ts targeting jagged canonical Notch ligand (JAG)1 and JAG2. Canonical tumor necrosis factor receptor superfamily member 17, Notch signaling activates the transcription of BMI1 proto-onco- CD19, CD22, CD30, CD79B, CD205, Claudin 18.2, fibro- gene polycomb ring finger, cyclin D1, CD44, cyclin dependent blast growth factor receptor (FGFR)2, FGFR3, receptor-type kinase inhibitor 1A, hes family bHLH transcription factor 1, tyrosine-protein kinase FLT3, HER2, hepatocyte growth factor hes related family bHLH transcription factor with YRPW receptor, NECTIN4, inactive tyrosine-protein kinase 7, inac- motif 1, MYC, NOTCH3, RE1 silencing transcription factor and tive tyrosine-protein kinase transmembrane receptor ROR1 transcription factor 7 in a cellular context-dependent manner, and tumor-associated calcium signal transducer 2. ADCs and while non-canonical Notch signaling activates NF-κB and Rac CAR-Ts could alter the therapeutic framework for refractory family small GTPase 1. Notch signaling is aberrantly activated cancers, especially diffuse-type gastric cancer, ovarian cancer in breast cancer, non-small-cell lung cancer and hematological and pancreatic cancer with peritoneal dissemination.
    [Show full text]
  • The Role of Cancer Stem Cells in Colorectal Cancer: from the Basics to Novel Clinical Trials
    cancers Review The Role of Cancer Stem Cells in Colorectal Cancer: From the Basics to Novel Clinical Trials Céline Hervieu 1 , Niki Christou 1,2 , Serge Battu 1 and Muriel Mathonnet 1,2,* 1 EA 3842 CAPTuR “Control of Cell Activation in Tumor Progression and Therapeutic Resistance”, Faculty of Medicine, Genomics, Environment, Immunity, Health and Therapeutics (GEIST) Institute, University of Limoges, 87025 Limoges CEDEX, France; [email protected] (C.H.); [email protected] (N.C.); [email protected] (S.B.) 2 Department of General, Endocrine and Digestive Surgery, University Hospital of Limoges, 87025 Limoges CEDEX, France * Correspondence: [email protected] Simple Summary: Cancer stem cells (CSCs) fuel tumor growth, metastasis and resistance to therapy in colorectal cancer (CRC). These cells therefore represent a promising target for the treatment of CRC but are difficult to study because of the complexity of their isolation. This review presents the methods currently used to isolate colorectal CSCs as well as the techniques for characterizing these cells with their advantages and limitations. The aim of this review is to provide a state-of-the-art on the clinical relevance of CSCs in CRC by outlining current treatments for CRC, the resistance mechanisms developed by CSCs to overcome them, and ongoing clinical trials of drugs targeting CSCs in CRC. Overall, this review addresses the complexity of studying CSCs in CRC research and developing clinically effective treatments to enable CRC patients to achieve a short and long-term therapeutic response. Citation: Hervieu, C.; Christou, N.; Battu, S.; Mathonnet, M. The Role of Abstract: The treatment options available for colorectal cancer (CRC) have increased over the years Cancer Stem Cells in Colorectal and have significantly improved the overall survival of CRC patients.
    [Show full text]
  • Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies
    Predictive QSAR tools to aid in early process development of monoclonal antibodies John Micael Andreas Karlberg Published work submitted to Newcastle University for the degree of Doctor of Philosophy in the School of Engineering November 2019 Abstract Monoclonal antibodies (mAbs) have become one of the fastest growing markets for diagnostic and therapeutic treatments over the last 30 years with a global sales revenue around $89 billion reported in 2017. A popular framework widely used in pharmaceutical industries for designing manufacturing processes for mAbs is Quality by Design (QbD) due to providing a structured and systematic approach in investigation and screening process parameters that might influence the product quality. However, due to the large number of product quality attributes (CQAs) and process parameters that exist in an mAb process platform, extensive investigation is needed to characterise their impact on the product quality which makes the process development costly and time consuming. There is thus an urgent need for methods and tools that can be used for early risk-based selection of critical product properties and process factors to reduce the number of potential factors that have to be investigated, thereby aiding in speeding up the process development and reduce costs. In this study, a framework for predictive model development based on Quantitative Structure- Activity Relationship (QSAR) modelling was developed to link structural features and properties of mAbs to Hydrophobic Interaction Chromatography (HIC) retention times and expressed mAb yield from HEK cells. Model development was based on a structured approach for incremental model refinement and evaluation that aided in increasing model performance until becoming acceptable in accordance to the OECD guidelines for QSAR models.
    [Show full text]
  • Characterization of Pulmonary Arteriovenous Malformations in ACVRL1 Versus ENG Mutation Carriers in Hereditary Hemorrhagic Telangiectasia
    © American College of Medical Genetics and Genomics ORIGINAL RESEARCH ARTICLE Characterization of pulmonary arteriovenous malformations in ACVRL1 versus ENG mutation carriers in hereditary hemorrhagic telangiectasia Weiyi Mu, ScM1, Zachary A. Cordner, MD, PhD2, Kevin Yuqi Wang, MD3, Kate Reed, MPH, ScM4, Gina Robinson, RN5, Sally Mitchell, MD5 and Doris Lin, MD, PhD5 Purpose: Pulmonary arteriovenous malformations (pAVMs) are mutation carriers to have pAVMs (P o 0.001) or multiple lesions major contributors to morbidity and mortality in hereditary (P = 0.03), and to undergo procedural intervention (P = 0.02). hemorrhagic telangiectasia (HHT). Mutations in ENG and ACVRL1 Additionally, pAVMs in ENG carriers were more likely to exhibit underlie the vast majority of clinically diagnosed cases. The aims of bilateral lung involvement and growth over time, although this did this study were to characterize and compare the clinical and not reach statistical significance. The HHT severity score was morphologic features of pAVMs between these two genotype significantly higher in ENG than in ACVRL1 (P = 0.02). groups. Conclusion: The propensity and multiplicity of ENG-associated Methods: Sixty-six patients with HHT and affected family pAVMs may contribute to the higher disease severity in this members were included. Genotype, phenotypic data, and imaging genotype, as reflected by the HHT severity score and the frequency were obtained from medical records. Morphologic features of of interventional procedures. pAVMs were analyzed using computed tomography angiography. Genet Med HHT symptoms, pAVM imaging characteristics, frequency of advance online publication 19 October 2017 procedural intervention, and HHT severity scores were compared Key Words: ACVRL1; ENG; genotype-phenotype correlation; between ENG and ACVRL1 genotype groups.
    [Show full text]
  • Form 10-Q Regeneron Pharmaceuticals, Inc
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES (X) EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2013 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ( ) EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number 0-19034 REGENERON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) New York 13-3444607 (State or other jurisdiction of (I.R.S. Employer Identification No.) incorporation or organization) 777 Old Saw Mill River Road, Tarrytown, New York 10591-6707 (Address of principal executive offices) (Zip Code) (914) 847-7000 (Registrant’s telephone number, including area code) Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes X No Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes X No Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.
    [Show full text]
  • An Endocytosis Pathway Initiated Through Neuropilin-1 and Regulated by Nutrient Availability
    ARTICLE Received 18 Apr 2014 | Accepted 2 Aug 2014 | Published 3 Oct 2014 DOI: 10.1038/ncomms5904 An endocytosis pathway initiated through neuropilin-1 and regulated by nutrient availability Hong-Bo Pang1, Gary B. Braun1,2, Tomas Friman1,2, Pedro Aza-Blanc1, Manuel E. Ruidiaz1, Kazuki N. Sugahara1,3, Tambet Teesalu1,4 & Erkki Ruoslahti1,2 Neuropilins (NRPs) are trans-membrane receptors involved in axon guidance and vascular development. Many growth factors and other signalling molecules bind to NRPs through a carboxy (C)-terminal, basic sequence motif (C-end Rule or CendR motif). Peptides with this motif (CendR peptides) are taken up into cells by endocytosis. Tumour-homing CendR peptides penetrate through tumour tissue and have shown utility in enhancing drug delivery into tumours. Here we show, using RNAi screening and subsequent validation studies, that NRP1-mediated endocytosis of CendR peptides is distinct from known endocytic pathways. Ultrastructurally, CendR endocytosis resembles macropinocytosis, but is mechanistically different. We also show that nutrient-sensing networks such as mTOR signalling regulate CendR endocytosis and subsequent intercellular transport of CendR cargo, both of which are stimulated by nutrient depletion. As CendR is a bulk transport pathway, our results suggest a role for it in nutrient transport; CendR-enhanced drug delivery then makes use of this natural pathway. 1 Cancer Research Center, Sanford-Burnham Medical Research Institute, La Jolla, California 92037, USA. 2 Center for Nanomedicine, Department of Cell, Molecular and Developmental Biology, University of California Santa Barbara, Santa Barbara, California 93106-9610, USA. 3 Department of Surgery, Columbia University, College of Physicians and Surgeons, New York, New York 10032, USA.
    [Show full text]
  • Multi-Modal Meta-Analysis of 1494 Hepatocellular Carcinoma Samples Reveals
    Author Manuscript Published OnlineFirst on September 21, 2018; DOI: 10.1158/1078-0432.CCR-18-0088 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Multi-modal meta-analysis of 1494 hepatocellular carcinoma samples reveals significant impact of consensus driver genes on phenotypes Kumardeep Chaudhary1, Olivier B Poirion1, Liangqun Lu1,2, Sijia Huang1,2, Travers Ching1,2, Lana X Garmire1,2,3* 1Epidemiology Program, University of Hawaii Cancer Center, Honolulu, HI 96813, USA 2Molecular Biosciences and Bioengineering Graduate Program, University of Hawaii at Manoa, Honolulu, HI 96822, USA 3Current affiliation: Department of Computational Medicine and Bioinformatics, Building 520, 1600 Huron Parkway, Ann Arbor, MI 48109 Short Title: Impact of consensus driver genes in hepatocellular carcinoma * To whom correspondence should be addressed. Lana X. Garmire, Department of Computational Medicine and Bioinformatics Medical School, University of Michigan Building 520, 1600 Huron Parkway Ann Arbor-48109, MI, USA, Phone: +1-(734) 615-5510 Current email address: [email protected] Grant Support: This research was supported by grants K01ES025434 awarded by NIEHS through funds provided by the trans-NIH Big Data to Knowledge (BD2K) initiative (http://datascience.nih.gov/bd2k), P20 COBRE GM103457 awarded by NIH/NIGMS, NICHD R01 HD084633 and NLM R01LM012373 and Hawaii Community Foundation Medical Research Grant 14ADVC-64566 to Lana X Garmire. 1 Downloaded from clincancerres.aacrjournals.org on October 1, 2021. © 2018 American Association for Cancer Research. Author Manuscript Published OnlineFirst on September 21, 2018; DOI: 10.1158/1078-0432.CCR-18-0088 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
    [Show full text]
  • Hereditary Hemorrhagic Telangiectasia: Diagnosis and Management From
    REVIEW ARTICLE Hereditary hemorrhagic telangiectasia: Ferrata Storti diagnosis and management from Foundation the hematologist’s perspective Athena Kritharis,1 Hanny Al-Samkari2 and David J Kuter2 1Division of Blood Disorders, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ and 2Hematology Division, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA ABSTRACT Haematologica 2018 Volume 103(9):1433-1443 ereditary hemorrhagic telangiectasia (HHT), also known as Osler- Weber-Rendu syndrome, is an autosomal dominant disorder that Hcauses abnormal blood vessel formation. The diagnosis of hered- itary hemorrhagic telangiectasia is clinical, based on the Curaçao criteria. Genetic mutations that have been identified include ENG, ACVRL1/ALK1, and MADH4/SMAD4, among others. Patients with HHT may have telangiectasias and arteriovenous malformations in various organs and suffer from many complications including bleeding, anemia, iron deficiency, and high-output heart failure. Families with the same mutation exhibit considerable phenotypic variation. Optimal treatment is best delivered via a multidisciplinary approach with appropriate diag- nosis, screening and local and/or systemic management of lesions. Antiangiogenic agents such as bevacizumab have emerged as a promis- ing systemic therapy in reducing bleeding complications but are not cur- ative. Other pharmacological agents include iron supplementation, antifibrinolytics and hormonal treatment. This review discusses the biol- ogy of HHT, management issues that face
    [Show full text]
  • Exploring the Extracellular Regulation of the Tumor Angiogenic Interaction
    bioRxiv preprint doi: https://doi.org/10.1101/581884; this version posted March 18, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC 4.0 International license. Exploring the extracellular regulation of the tumor angiogenic in- teraction network using a systems biology model Ding Li1 and Stacey D. Finley2 1Department of Biomedical Engineering, University of Southern California, Los Angeles, CA, USA 2Department of Biomedical Engineering; Mork Family Department of Chemical Engineering and Materials Sci- ence; Department of Biological Sciences, University of Southern California, Los Angeles, CA, USA ABSTRACT angiogenic signaling to oppose angiogenesis4,5. Considering Tumor angiogenesis is regulated by pro- and anti-angiogenic factors. the importance of angiogenesis in tumor development, anti- Anti-angiogenic agents target the interconnected network of angio- angiogenic therapies are designed to target the signaling of genic factors to inhibit neovascularization, which subsequently im- angiogenic factors to inhibit neovascularization and tumor pedes tumor growth. Due to the complexity of this network, optimizing growth6. Single-agent anti-angiogenic therapies that target a anti-angiogenic cancer treatments requires detailed knowledge at a particular angiogenic factor in the network were the first angi- systems level. In this study, we constructed a tumor tissue-based ogenesis-inhibiting therapies studied. These include antibod- model to better understand how the angiogenic network is regulated ies or small molecules targeting pro-angiogenic factors7 and by opposing mediators at the extracellular level. We consider the net- peptide mimetics of anti-angiogenic factors8.
    [Show full text]
  • Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
    CLASSIFICATION DECISIONS TAKEN BY THE HARMONIZED SYSTEM COMMITTEE FROM THE 47TH TO 60TH SESSIONS (2011 - 2018) WORLD CUSTOMS ORGANIZATION Rue du Marché 30 B-1210 Brussels Belgium November 2011 Copyright © 2011 World Customs Organization. All rights reserved. Requests and inquiries concerning translation, reproduction and adaptation rights should be addressed to [email protected]. D/2011/0448/25 The following list contains the classification decisions (other than those subject to a reservation) taken by the Harmonized System Committee ( 47th Session – March 2011) on specific products, together with their related Harmonized System code numbers and, in certain cases, the classification rationale. Advice Parties seeking to import or export merchandise covered by a decision are advised to verify the implementation of the decision by the importing or exporting country, as the case may be. HS codes Classification No Product description Classification considered rationale 1. Preparation, in the form of a powder, consisting of 92 % sugar, 6 % 2106.90 GRIs 1 and 6 black currant powder, anticaking agent, citric acid and black currant flavouring, put up for retail sale in 32-gram sachets, intended to be consumed as a beverage after mixing with hot water. 2. Vanutide cridificar (INN List 100). 3002.20 3. Certain INN products. Chapters 28, 29 (See “INN List 101” at the end of this publication.) and 30 4. Certain INN products. Chapters 13, 29 (See “INN List 102” at the end of this publication.) and 30 5. Certain INN products. Chapters 28, 29, (See “INN List 103” at the end of this publication.) 30, 35 and 39 6. Re-classification of INN products.
    [Show full text]
  • Neuropilin-1
    November 3, 2020 Edition 2020-11-03 *** Available on-line at https://www.cdc.gov/library/covid19 *** Neuropilin-1 The SARS-CoV-2 major spike protein (S) is cleaved by a host protease to create S1 and S2 functional polypeptides. The S1 polypeptide has a carboxy-terminal sequence that binds to host cell surface neuropilin-1 (NRP1) and neuropilin-2 (NRP2) receptors. NRP receptors facilitate viral entry for several viruses due to their abundance on cells that are exposed to the external environment – cells that paradoxically express low levels of angiotensin- converting enzyme-2 (ACE2), the known SARS-CoV-2 receptor. Here we present two articles that evaluated the potential for NRP1 to act as a co-receptor for SARS-CoV-2. PEER-REVIEWED Neuropilin-1 is a host factor for SARS-CoV-2 infection. Daly et al. Science (October 20, 2020). Key findings: • The S1 fragment of the cleaved SARS-CoV-2 spike protein binds to the cell surface receptor neuropilin-1 (NRP1). • SARS-CoV-2 utilizes NRP1 for cell entry as evidenced by decreased infectivity of cells in the presence of: o NRP1 deletion (p <0.0001) (Figure). o Three different anti-NRP1 monoclonal antibodies (p <0.001). o Selective NRP1 antagonist, EG00229 (p <0.01). Methods: Binding of the S1 fragment to NRP1 was assessed and ability of SARS-CoV-2 to use NRP1 to infect cells was measured in angiotensin-converting enzyme-2 (ACE-2)-expressing cell lines by knocking out NRP1 expression, blocking NRP1 with 3 different anti-NRP1 monoclonal antibodies, or using NRP1 small molecule antagonists.
    [Show full text]